

# Diabetes Specific Nutrition Formula (DSNF) For Diabetes Management & Cost Reduction

Osama Hamdy, MD, PhD, FACE

Medical Director, Obesity Clinical Program,  
Director Inpatient Diabetes Program,  
Joslin Diabetes Center  
Associate Professor of Medicine,  
Harvard Medical School, Boston, MA



*“Let thy food be thy medicine, and  
let thy medicine be thy food.”*

*Hippocrates, father of medicine*



# THE LANCET

---

## Diabetes 1



### Prevention and management of type 2 diabetes: dietary components and nutritional strategies

*Sylvia H Ley, Osama Hamdy, Viswanathan Mohan, Frank B Hu*


Vol 383 June 7, 2014



**Joslin Diabetes Center**




# Summary of Meta-analysis of Prospective Studies of Nutrient Intake and Glycemic Variables and Type 2 Diabetes



DHA=docosahexaenoic acid EPA-eicosapentaenoic acid. Relative risks are comparison of extreme categories, except DHA/EPA (per 250 mg per day increase) and alpha-linolenic acid (per 0.5 g per day).


All nutrients and glycemic variables were assessed from dietary intake, except vitamin D for which blood 25hydroxyvitamin D was used.

# Summary of Meta-analysis of Prospective Cohort Studies on Food and Beverage Intake and Type 2 Diabetes



Relative risks are comparison of extreme categories, except for processed meat (per 50 g per day increase), unprocessed red meat and fish or seafood (per 100 g per day), white rice (per each serving per day), whole grains (per three servings per day), sugar-sweetened beverages in European cohorts (per 336 g per day), and alcohol (22 g per day for men and 24 g per day for women with abstainers)

# Dietary intervention for Patients with Type 2 Diabetes



# Diabetes-Specific Formulas (DSFs) are designed to improve glucose control

Diabetes-Specific	Standard
Defined nutrient composition to enable better glycemic control	May compromise glycemic control in patients with diabetes
Modified carbohydrate ( <b>low glycemic</b> )	High in rapidly digested carbohydrate ( <b>high glycemic</b> )
Modified fat: favors monounsaturated (MUFA) fats	Lower fat
May reduce need for additional insulin to maintain good glycemic control <sup>1,2</sup>	May require more attention to maintain glucose control
Clinically demonstrated efficacy in people with diabetes	Limited efficacy demonstrated in people with diabetes


1. Elia M, et al. *Diabetes Care*. 2005;28(9):2267–2279.

2. Mesejo A, et al. *Crit Care*. 2015;19:390. doi: 10.1186/s13054-015-1108-1.



## COSTS OF DIABETES

- Total estimated cost of diabetes in 2012 was \$245 billion (41% up from 2007), with \$176 billion direct cost and 69 billion reduced productivity
- Largest component of medical expenditures attributed to diabetes was **hospital inpatient care (~43% of costs)**



# **Differences in Resource Utilization Between Diabetic Patients Receiving Diabetes-Specific Nutrition Formula Versus Standard Nutrition Formula In US Hospitals**




# Objective and Methods

## ■ Design

- Retrospective review of all inpatients within Premier Research Database
- N=>500 geographically diverse hospitals
- Comparisons made between:
  - Diabetic patients fed diabetes specific formula (DSNF)
  - Diabetic patients fed standard nutrition (STD)

# Population Flow



# Results

- Feeding DSF to patients with diabetes results in significant\* improvement in patient efficiency and cost of care


Savings from feeding DSF rather than STD formula	
Per patient	Tube Fed DSNFs
Average Length of Hospital Stay	-0.9 days
Total Hospital Costs	-\$2,586

\* Average LOS and hospital cost statistically significant at  $P < 0.001$

Per patient	Oral Fed DSNFs
Average Length of Hospital Stay	-0.17 days
Total Hospital Costs	-\$1,356

# Using DSNF drives reduction in room & board, pharmacy, and labor costs for tube fed patients

Tube Fed PWD - \$2,586 total savings per patient



Note: Analysis adjusted the Other cost consistent with total cost savings since all costs independently modeled. Other costs include Surgery, Lab, Diagnostic Imaging, and Cardiology. All cost values statistically significant at  $P < 0.0001$  except TF Central Supply Costs ( $P < 0.003$ ). N for each sample population > 30k



# Expert recommendations for DSF

## 14. Diabetes Care in the Hospital: *Standards of Medical Care in Diabetes—2018*

*Diabetes Care* 2018;41(Suppl. 1):S144–S151 | <https://doi.org/10.2337/dc18-S014>



*“Regarding enteral nutritional therapy, **diabetes-specific formulas appear to be superior** to standard formulas in controlling postprandial glucose, A1C and the insulin response.”*

Review Clin Nutr. 2017 Apr;36(2):355-363

Carbohydrates and insulin resistance in clinical nutrition:  
Recommendations from the ESPEN expert group



*“Based on this available evidence, the ESPEN expert group **endorses the utilization of DSFs for nutritional support of people with obesity and diabetes.**”*




Joslin Diabetes Center



# Significant Reduction in Weight By DSF in Patients With Diabetes in Association With Reduction in Glycemic Variability

## Changes in Weight



DSN = diabetes-specific nutrition.

\*Data logarithmically transformed for analysis.

Tatti P, et al. *Med J Nutrition Metab.* 2010;3:65-69.



Joslin Diabetes Center




# Significant Reduction in HbA1c By DSF in Patients With Diabetes in Association With Reduction in Glycemic Variability

## Changes in HbA1c




-0.3%  
A1c

# Strong Correlation Between Meal Replacements and Weight Loss (Look AHEAD Study)




MRs = meal replacements

## Estimated Cost-Saving After Why WAIT Program for 1 Year



Health Care Cost Diabetes Related Cost


# Effect of Different Diabetes-specific Formulas Versus Oatmeal on Plasma Glucose Area Under the Curve (AUC)



N=22  
Each meal is 200 Kcal  
\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$  Versus Oatmeal  
† $p < 0.05$ , †† $p < 0.01$ , ††† $p < 0.001$  Between Glucerna & Ultra-Glucose control


AUC 0-240 (Area Under the Curve)  
Oatmeal = 5933.3  
Glucerna = 1684.2\*\*\*  
Ultra-Glucose Control = 3351.1\*\*\*

# Insulin



Positive AUC0-120 was significantly higher Formula 2 than after OM ( $p=0.02$ )


# GLP-1



Positive AUC<sub>0-240</sub> was significantly higher after both formulas than after OM ( $p < 0.001$  for both)




# PYY



Positive AUC0-240 was significantly higher after both formulas than after OM ( $p < 0.001$  for both)


# Amylin (active)



# Nutrition Path Study



# Structured Meal Plan



# Nutrition Therapy

**Group A**

Meet RD



Individualized  
Meal Plan

**Group B**

Meet RD



Structured  
Meal Plan

**Group C**

Meet RD




Structured  
Meal Plan

+




Weekly phone call


# A1C





# Weight loss



# Abdominal Adiposity



# Incretin Therapies: Major Differences

	Properties/Effect	GLP-1 Receptor Agonists <sup>1,2</sup>	DPP-4 Inhibitors <sup>1,2</sup>	MNT with DSF
	↑ Insulin production	+++	++	++
	↑ Amylin	NO	NO	+
	↑ GLP-1 ↑ PYY	- NO	+ NO	++ ++
	Gastric emptying	Delayed	No effect	NO
	Food intake	↓	No effect	↓
	Body weight	↓	No effect	↓
	Visceral Fat	NO	NO	↓
	Side effects	Nausea, vomiting	Minimal	NO

1. DeFronzo RA et al. *Curr Med Res Opin.* 2008; 24:2943-2952.

2. Drucker DJ & Nauck MA. *Lancet.* 2006;368:1696-1705.

# Diabetes Care.

WWW.DIABETES.ORG/DIABETESCARE

JANUARY 2017

SUPPLEMENT  
**1**

AMERICAN DIABETES ASSOCIATION

## STANDARDS OF MEDICAL CARE IN DIABETES—2019

 American  
Diabetes  
Association.  
ISSN 0149-5992

“Medical Nutrition Therapy (MNT) throughout the course of **a structured weight loss plan, is strongly recommended**”

“Studies have demonstrated that a variety of eating plans, varying in macronutrient composition, can be used effectively and safely in short term (1-2 years) to achieve weight loss in people with diabetes. This includes structured **low-calorie meal plans that include meal replacements**”



# Clinical evidence from RCTs indicate that DSNF, as suggested medical food, improves outcomes in patients with diabetes



DSNF<sub>1-5</sub>

- Better postprandial glucose control
- Increase GLP-1 and satiety hormones
- Lower A1C
- Reduce glycemic variability
- Reduce body weight
- Reduced insulin requirements
- Reduce LOS and hospital cost

GLP-1=glucagon-like peptide; HbA1c=glycated hemoglobin.





Thank You